standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
ABI-H0731-211
Phase 2 small_molecule terminated
Quick answer
standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI) for Chronic Hepatitis B is a Phase 2 program (small_molecule) at ASSEMBLY BIOSCIENCES, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ASSEMBLY BIOSCIENCES, INC.
- Indication
- Chronic Hepatitis B
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated